Loading...
Loading...
- IDEXX Laboratories Inc IDXX reported Q4 FY22 sales of $829 million, up 3% Y/Y, beating the consensus of $820.91 million. Adjusted EPS was $2.07, beating the consensus.
- CAG Diagnostics recurring revenue gains of 4% reported and 8% organic in the quarter were supported by continued benefits from IDEXX execution drivers.
- CAG revenue gains also reflect veterinary software, services, and diagnostic imaging systems revenue growth of 15% as reported and 17% organically, supported by software solution placement growth and a continued shift to cloud-based products.
- For FY23, the company expects revenue of $3.59-$3.69 billion, compared to the consensus of $3.62 billion.
- IDEXX forecasts an EPS of $9.27-$9.75 compared to the Wall Street Estimate of $9.50.
- William Blair notes the veterinary healthcare market as a relatively safe-haven investment area for investors, with IDXX’s strong balance sheet, solid free cash flow profile, impressive ROIC characteristics, and mainly recurring revenue model remaining highly appealing.
- The analyst writes that solid fourth quarter performance and 2023 commentary strengthen the conviction in the company’s growth trajectory and sees IDXX as a core long-term holding while reiterating the Outperform rating on the stock.
- Price Action: IDXX shares are up 1.99% at $491.99 on the last check Monday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in